
Trump Sends Cannabis Stocks Surging, Cantourage Brings in Investor Relations Help, & Mamedica Secures £4.5m
Cannabis Stocks Surge on Trump Video Global cannabis stocks have enjoyed a considerable, but likely temporary, run this week, after

Cannabis Stocks Surge on Trump Video Global cannabis stocks have enjoyed a considerable, but likely temporary, run this week, after

There is a frustrating misimpression circulating in the cannabis community regarding rescheduling. Many headlines state that Trump is considering finishing

Cannabis stocks across North America have skyrocketed to their highest point so far this year, despite a lukewarm promise from

The cannabis industry is once again awash with hope and speculation over the promise of rescheduling following reports that President Trump has promised the industry that ‘it’s something we’re going to look at’.

Amid rising global scrutiny of the wider medical cannabis prescription model, and with markets like France leaning into pharmaceutical-grade regulation, the pharma cannabis sector is shaping up to be one of the most dynamic and closely watched corners of the industry.

The US cannabis rescheduling project, which has been stuck in limbo since being ‘temporarily’ shelved six months ago, is now facing another existential threat from the government’s wide reaching budget.

The Trump administration’s ‘One Big Beautiful Bill’, the federal government’s annual spending and tax omnibus legislation, has quietly dropped a key piece of legislation putting the country’s entire medical cannabis industry under threat.

The shock announcement this week that a federal trade court had ruled that key elements of President Trump’s flagship tariff

The US Cannabis Roundtable (USCR), one of the most influential advocacy groups in the country, is ‘still optimistic about the President acting on cannabis reform’.

Licensed cannabis operators and ancillary companies are bracing for rising business costs, lost customers and vendor backlash in the wake of President Donald Trump’s erratic blanket tariffs that have rattled the global economy and stoked fears of a recession and accelerated inflation in the United States.

The incomprehensible economic strategy of President Trump’s global tariffs has left almost every US industry scratching their heads, and fearing

‘Liberation day’, set to take place on April 02, has been pitched as the day the Trump administration will roll out sweeping and aggressive tariffs for all of the US’ trading partners.

A proposal for federal legalization of cannabis is now expected to be submitted to the White House by the end of the week, driving a bump in US cannabis stocks.

The largest bipartisan coalition of cannabis advocacy, industry, and grassroots organizations, is set to descend on the US capital for

The Trump administration’s confusing and often contradictory position on drug reform has gotten even more opaque, as the President has called for the death penalty to be applied to drug dealers.

A new US administration, China’s AI upset, and now a looming trade war have played havoc with the stock market

This week has seen another frenetic torrent of executive orders issued by the newly inaugurated President Trump, causing chaos across almost all of America’s cornerstone institutions.

As the furor surrounding the US presidential election subsides, the president elect’s preliminary picks for his cabinet have given the cannabis industry a glimpse into what it can expect for reform in the US over the next four years.